Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2017

View Archived Issues

Astellas reflects on accomplishments of fourth quarter of fiscal 2016

Roche reports key milestones of first quarter 2017

Daiichi Sankyo invests in manufacturing capabilities to support ADC pipeline

ENCORE 601 trial expands to include colorectal cancer cohort

Propanc Biopharma completes 28-day, repeat-dose toxicity study for PRP

Immune Pharmaceuticals restructures to focus on inflammatory disease and dermatology

European Commission approves Darzalex in combination therapy for multiple myeloma

Sorrento's TNK Therapeutics closes acquisition of Virttu Biologics

SkQ1 ophthalmic solution improves visual acuity in patients with Leber's hereditary optic neuropathy

FDA grants accelerated approval to Imfinzi for previously treated bladder cancer

Urumin, an anti-influenza virucide with efficacy in drug-resistant H1 influenza strains

Shire licenses rights to P-321 for ophthalmic indications

Phase III results for brexpiprazole to treat agitation related to Alzheimer's-type dementia

MSD K.K. seeks Japanese approval of Keytruda for locally advanced or metastatic urothelial cancer

FDA approves Rydapt for patients with newly diagnosed AML with FLT3 mutation

European Commission approves Opdivo for squamous cell cancer of the head and neck

Cerecor reports proof-of-concept data on CERC-501 in treatment-resistant depression

Daiichi Sankyo initiates phase I study of DS-3201b for AML and ALL

FDA grants accelerated approval to Alunbrig for ALK-positive NSCLC

Trial finds urolithin A safe in healthy elderly subjects

Neurotrope reports phase II topline results for bryostatin 1 in moderate to severe Alzheimer's

ZoptEC phase III study of Zoptrex in endometrial cancer does not meet primary endpoint

Jiangsu Nhwaluokang Pharmaceutical Research & Development patents etomidate derivatives

Pfizer's novel EZH2 inhibitor PF-6821497 selected for clinical development

Almirall discovers TRPA1 antagonists

Hetero Research Foundation identifies antiviral agents

NHWD-870 is a promising novel BET family bromodomain inhibitor against a broad spectrum of cancers

Bristol-Myers Squibb presents PD-L1/PD-1 and/or PD-L1/CD80 interaction inhibitors

GlaxoSmithKline divulges BRD4 inhibitors

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...